Participation in pharmaceutical costs and seniors' access to medicines in the Czech Republic
Language English Country Czech Republic Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
18459476
DOI
10.21101/cejph.a3439
Knihovny.cz E-resources
- MeSH
- Healthcare Disparities economics MeSH
- Health Services Accessibility economics MeSH
- Middle Aged MeSH
- Humans MeSH
- Cost Sharing MeSH
- Insurance, Pharmaceutical Services economics MeSH
- Fees, Pharmaceutical * MeSH
- National Health Programs MeSH
- Aged MeSH
- Socioeconomic Factors MeSH
- Health Services for the Aged economics MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic MeSH
OBJECTIVES: Analysis of participation in drug costs by seniors in the Czech Republic in connection with seniors' access to pharmacotherapy. MATERIALS AND METHODS: Quota-sampled guided interview with 450 respondents visiting pharmacy; ratio of men and women approximately 1:2; age over 60 years; 3 regions of the Czech Republic. RESULTS: Respondent's income was retirement pension in 80%. More than 55% of respondents did not reach the official state average. Respondents used altogether 1,650 medicines on physician's prescription in the last four weeks. Overall co-payment for medicines was 38,778 CZK, i.e. 86 CZK per patient. Only 27% of respondents used fully reimbursed products. Respondents used together 273 OTC drugs (over-the-counter drugs, e.g. non prescription drugs) in value of 16,540 CZK, i.e. 37 CZK per patient. Average respondent spent on medicines 123 CZK in the last four weeks, i.e. 1.5% of the official state average income. There were respondents, about 10%, searching for the level of co-payment in several pharmacies and more than 8% of respondents had to refuse dispensation of medicines due to co-payment. CONCLUSIONS: Our study demonstrates that there are patients who may fail to gain access to medication due to co-payment in the Czech Republic. The financial participation in health care costs is generally low in the Czech Republic (8.8% of total health expenditures) but there were differences in co-payment levels in patients ranging from 1 CZK to thousands CZK. In our opinion problem might be in the absence of any instrument limiting the highest individual participation as it is for example in 12-month period in Sweden. In our study co-payments were lower in smaller communities that may be due to better communication between physicians and patients or physicians and pharmacists. We found a critical ethical problem in different levels of co-payment of concrete product.
References provided by Crossref.org